Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics Inc's strategic focus on developing novel antiviral therapies positions it favorably within the biotechnology industry, particularly for conditions like fibromyalgia and long COVID. The recent licensing agreement with Serpin Pharma for SP16, enhancing the company's portfolio in cancer-related pain management, signifies potential revenue growth opportunities and opens avenues for collaboration with development partners. Furthermore, the raising of the 12-month price target to $12.00, reflecting positive future revenue projections, underscores a bullish sentiment regarding the company's financial outlook.

Bears say

Dogwood Therapeutics Inc., a development-stage biotechnology company, is focused on developing antiviral therapies but currently lacks commercialized products to generate revenue, contributing to financial instability. The company's reliance on novel therapies for conditions like fibromyalgia and long COVID may pose significant risks, given the competitive nature of the biotechnology sector and potential regulatory hurdles. Although a low dropout rate of 4.4% suggests some patient satisfaction, it does not sufficiently mitigate the challenges associated with achieving profitability and advancing product candidates through clinical trials.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.